**C3RN News Summary – May 6th, 2019**

Research

1. A study on the use of cannabidiol in patients with treatment-resistant epilepsy found that “all doses were generally well tolerated, and common adverse events that occurred at > 10% were somnolence (21.3%), anemia (18.0%), and diarrhea (16.4%).”

(University of Tennessee Health Science Center) (May 2)

[More...](https://www.ncbi.nlm.nih.gov/pubmed/31049885)

2. A study done on cannabis use concurrent with exercise “found that the majority of participants who endorsed using cannabis concurrently with exercise reported that doing so at least somewhat enhances recovery from and enjoyment of exercise, while approximately half reported that it at least somewhat increases motivation, and a minority reported that it enhances performance.”

(Apr 30) (Department of Psychology & Neuroscience, University of Colorado)

[More...](https://www.frontiersin.org/articles/10.3389/fpubh.2019.00099/full)

3. A recently updated review of research relating to the safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders states that “randomised controlled trials of plant-derived cannabidiol for treatment of Lennox-Gastaut syndrome and Dravet syndrome, two severe childhood-onset epilepsies, provide evidence of anti-seizure effects. However, small clinical trials of cannabinoids in other neurological disorders such as Huntington's disease, attention deficit hyperactivity disorder, and dementia, have not found any effect.”

(New York University Langone School of Medicine) (May 1)

[More...](https://www.ncbi.nlm.nih.gov/pubmed/30910443)

Industry News

1. MIT and Harvard get a 9M private grant to research cannabis and its effects on the brain. The individual providing the grant, Bob Broderick, believes that cannabis companies “haven’t been backing research to understand the basic biology of cannabis,” rather they focus on how cannabis can be used to treat certain medical conditions.” (WBUR) (Apr 30)

[More...](https://www.wbur.org/commonhealth/2019/04/30/broderick-cannabis-science-harvard-mit)

2. Researchers note that cannabis used for clinical testing by the DEA may vary from consumer product. An article from Nature notes that “The agency’s crop ‘doesn’t look like marijuana, it doesn’t smell like marijuana’, says Anna Schwabe, a plant geneticist at the University of Northern Colorado in Greeley, who co-authored the study comparing cannabis genomes.”

(Nature) (May 2)

[More...](https://www.nature.com/articles/d41586-019-01415-z#ref-CR1)